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Abstract
Low grade gliomas (LGGs) are infiltrative and incurable primary brain tumours
with typically slow evolution. These tumours usually occur in young and oth-
erwise healthy patients, bringing controversies in treatment planning since ag-
gressive treatment may lead to undesirable side effects. Thus, for management
decisions it would be valuable to obtain early estimates of LGG growth poten-
tial.
Here we propose a simple mathematical model of LGG growth and its re-
sponse to chemotherapy which allows the growth of LGGs to be described in
real patients. The model predicts, and our clinical data confirms, that the speed
of response to chemotherapy is related to tumour aggressiveness. Moreover, we
provide a formula for the time to radiological progression, which can be possibly
used as a measure of tumour aggressiveness.
Finally, we suggest that the response to a few chemotherapy cycles upon
diagnosis might be used to predict tumour growth and to guide therapeutical
actions on the basis of the findings.
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1. Introduction
Low grade gliomas (LGGs) are slowly growing tumours which arise from
supporting glial cells in the brain. Although they proliferate slowly, the ul-
timate behaviour of these tumours is not benign. They are almost invariably
incurable due to their diffusive infiltrative nature and often lead to patient death
due to malignant transformation, i.e. transformation of the tumour into more
aggressive anaplastic form.
Treatment of LGGs is controversial among clinicians as LGGs usually occur
in young and otherwise healthy patients. Besides seizures, patients with LGGs
appear neurologically asymptomatic. Thus, life-prolonging treatment should
not come at the cost of compromising the quality of life of these otherwise
healthy and mostly young patients. Management decisions, whether a patient
with LGG should receive resection, radiation therapy or chemotherapy, are not
fully standardized. Clinicians usually base their decisions about extent of surgi-
cal resection, timing of radiotherapy and long-term benefits and risks of chemo-
therapy on a large number of factors including age, performance status, location
of tumour and patient preference.
Current standard of care is first to perform maximal resection with minimum
impact on the brain’s functional areas. Support for such an approach comes
from studies which demonstrate that the extent of resection is a prognostic fac-
tor for LGG patients [1, 2]. Unfortunately, because of the LGGs infiltrative
characteristics, surgery alone fails to cure these tumours in most cases as only
the tumour bulk can be resected. There is a trend to use more active treat-
ments and various alternative approaches have been considered. Post-operative
radiotherapy could be a therapeutic option for low-grade gliomas, but it causes
long-term neurocognitive toxicity and fails to show a significant improvement
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in patient survival [3–5]. Therefore radiotherapy is usually deferred and per-
formed routinely only in patients with tumours facing a high risk of malignant
transformation [6].
In this context, there is an increasing interest in the use of chemotherapeutic
agents which could influence tumour evolution and at the same time allow the
delay of more aggressive treatments. Currently there are two chemotherapeu-
tic drugs effective for the treatment of glioma patients: temozolomide (TMZ),
an oral alkylating agent and procarbazine, lomustine and vincristine (PCV),
a combination of alkylating agents and cell-cycle specific microtubule inhibitor.
About 25-50% of LGGs show chemotherapeutic responses to treatment with
either TMZ or PCV. PCV has been used from the 1970’s and has been sug-
gested as a clinically relevant option especially for some subtypes of anaplastic
gliomas with the 1p/19q codeletion [7, 8]. Unfortunately it causes significant
myelosuppression, nausea and peripheral neuropathy [9, 10].
TMZ is a cell-cycle non-specific prodrug, absorbed with almost 100% bioavail-
ability [11]. This chemotherapeutic agent can cross the blood-brain barrier and
is spontaneously converted in tumour cells to its active metabolite [12]. The
main cytotoxic action of TMZ occurs at the O6− position of guanine. During
subsequent cycles of replication, the futile mismatch repair system is initiated
and O6MeG is incorrectly paired with thymine instead of cytosine, eventually in-
ducing cell death, see e.g. [13, 14]. A phase III trial showed the efficacy of TMZ
for high-grade gliomas [15] and since then it has been used routinely for patients
with newly diagnosed glioblastoma (the most malignant type of glioma) [16].
Phase II trials have demonstrated its effectivity against both previously irra-
diated and unirradiated LGGs [17–19]. In addition, there are reports of cases
where neoadjuvant chemotherapy given to surgically unresectable tumours has
allowed subsequent gross total resection [20, 21], which is of great importance
especially when the tumour is highly infiltrative or located in eloquent areas.
Large prospective studies with long-term follow-up are under development to
verify statistically significant improvement in resections following TMZ treat-
ment. It has also been reported that TMZ treatment may lead to an important
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reduction in seizure frequency in LGG patients [22]. Thus prolonged TMZ treat-
ment until evidence of resistance is a clinically interesting option for selected
patients as an up-front or adjuvant treatment. Clinical trials are on the way to
study the effect of this treatment on survival.
Temozolomide has a better toxicity profile than PCV, being well tolerated
by patients [19, 23, 24]. This is due to the fact that, in contrast to procarbazine
and lomustine, TMZ does not cause a chemical cross-linking of the DNA strands
and it is less toxic to the haematopoietic progenitor cells in the bone marrow
[25]. Patients treated with TMZ are also seeing a reduced risk of cumulative
haematologic toxicity thanks to the rapid elimination of this drug [11, 25, 26].
The response of glioma cells to chemotherapy is a subject of many clinical
and biological studies. Recently, it has been shown that in some LGG patients
a metabolic response to TMZ therapy is observed even 3 months after the end
of the treatment [27, 28]. Moreover, dynamic volumetric studies have shown
that a treatment-related volume decrease can be observed for many months af-
ter the chemotherapy is discontinued [29, 30]. The time to maximum tumour
response was reported to be in some cases larger than 2 years [31]. Other re-
searchers investigated relations between some molecular characteristics of LGGs
and response to TMZ [18, 30, 32, 33]. However, the question of the correct tim-
ing of chemotherapy remains unanswered, namely whether it should be given
first or when progression has been observed. Another issue to be addressed
is the optimal fractioning of TMZ.
The typical plan of TMZ treatment is to give doses of 150–200 mg per m2 of
patient body surface once per day for 5 days every 28 consecutive days. The
number of such cycles in clinical practise is usually between 12 and 30 [30, 31, 34]
and it depends on patient-related characteristics and the haematological toxi-
city observed. There have been many clinical studies on alternative treatment
regimens for gliomas. Among others in [17] patients were treated in cycles with
doses of 75 mg/m2 given daily for 7 weeks followed by four-week breaks. Some
trials on dose escalation [35–37] intended to overcome the DNA-repair activity
of the enzyme MGMT (O6MeG methyltransferase), which reverses alkylation
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at the O6 position of guanine [38, 39]. However, these TMZ regimes were either
not effective or had to be rejected because of a high toxicity [40]. Recent studies
show that O6MeG is able to trigger not only apoptosis (programmed cell death),
but also autophagy (mechanism allowing the degradation and recycling of cel-
lular components) and senescence (state of permanent cell-cycle arrest in which
cells are resistant to apoptotic death) [41], which may provide an explanation
why previous studies failed to improve treatment efficacy. Many clinicians con-
clude that the chemotherapy fractionation scheme providing the best tumour
response and acceptable haematologic toxicity are still to be determined.
Mathematical modelling has great potential to help in finding appropriate
therapeutic timings and/or fractionations and in individual patient treatment
decision. Even models simple from mathematical point of view can be useful
for clinical practice.
In this paper we describe a simple mathematical model for LGG growth and
response to chemotherapy that fits very well with longitudinal volumetric data
of patients diagnosed with LGGs. Interestingly, the model suggests that the
response of the tumour to chemotherapy may be related to its aggressiveness.
We also provide an approximate explicit formula for the time of tumour response
to chemotherapy. This equation may be helpful to clinicians in selecting patients
who will benefit most from early treatment and finding the best personalised
therapy.
Our plan in this paper is as follows: in Section 2 we develop the model and
describe its parameters. In Section 3 we present the results of model fitting to
patient data and suggest the relation between time of response to chemotherapy
and patient prognosis. The analytical estimates are shown in Section 4. We
discuss the results of our model and therapeutic implications in Section 5.
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2. Mathematical model
2.1. The dynamics of tumour cells
Computational modelling of glioma growth started 20 years ago [42] and
has received strong attention in the last few years (see e.g. [43–47]). For solid
tumours mathematical models have considered different chemotherapy-related
factors such as drug diffusion, uptake/binding, clearance and their effect on
cell cycle progression (see e.g. [48–51]). Many mechanistic mathematical mod-
els models have been developed to improve the design of chemotherapy regimes
(see e.g. [52] for a summary). However, very few models have considered chemo-
therapy of LGGs [34].
In order to keep our description as simple as possible we will build a continu-
ous macroscopic model assuming that the tumour grows due to net cell division.
The simplest choice for the proliferative term is to assume that a tumour cell
number P (t) is governed by a logistic growth with coefficient ρ, its inverse giving
an estimate of the typical cell doubling times.
TMZ is a small molecule and is easily absorbed in the digestive tract with
100% of bioavailability and a half-life of absorption of 7 minutes [53]. It should
be noted that the intact TMZ molecule easily crosses the blood brain barrier due
to its lipophilicity, and is then activated in the brain compartment. It hydrolyses
to MTIC, which subsequently undergoes spontaneous breakdown to an inactive
metabolite AIC and an active methyldiazonium cation. It is the methyldiazo-
nium ion that causes the damage in patients’ DNA, namely it transfers methyl
groups to DNA. The most common sites of methylation are the N7 position of
guanine (N7-MeG; 60-80%) followed by the N3 position of adenine (N3-MeA;
10-20%) and the O6 position of guanine (O6-MeG; 5-10%) [54], the last one
being responsible for major cytotoxicity.
As to the TMZ effect on tumour cells, we choose here to formulate a macro-
scopic model. It is known that TMZ-induced damage leads to cell death long
after the end of therapy [29–31, 55]. It has been verified in vitro that the glioma
cells death after administration of TMZ is induced most typically in one of the
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post-treatment cell cycles [56] due to futile mismatch repair cycles (see e.g. [12]
for a detailed description of this mechanism). This delayed cell death is a key
feature of glioma response to chemotherapy. Thus, in line with this biological
evidence we will assume that tumour cells treated with chemotherapy die after
a time k/ρ of the order of mean k effective tumour doubling times. This type
of model has been used successfully to describe the effect of radiotherapy on
LGGs [57, 58].
Then, we will complement the equation for the number of functionally alive
tumour cells P (t) with an equation for the evolution of the number of cells
irreversibly damaged by chemotherapy D(t). The number of cells damaged by
the drug in a time unit is considered to be proportional to the concentration of
the drug C(t) multiplied by the number of proliferating tumour cells with the
rate α, measuring the influence of TMZ on cells. We assume that irreversibly
damaged tumour cells try to enter mitosis with the same probability as those
active, but die after a mean value of k such attempts, which results in the
growth rate ρ
(
1− P+DK
)
for proliferative cells and the death rate− ρk
(
1− P+DK
)
for damaged cells, K being the carrying capacity for both populations P +D,
which leads to the following set of equations
dP
dt
= ρP
(
1−
P +D
K
)
− αPC, (1a)
dD
dt
= −
ρ
k
D
(
1−
P +D
K
)
+ αPC, (1b)
where C(t) accounts for the brain chemotherapy concentration to be described
in more details later. Taking an average cell volume, we can easily treat the
tumour mass P + D as the total tumour volume, which is easier to compare
with results obtained from magnetic resonance imaging (MRI), usually used in
brain tumour diagnosis and follow-up observation.
2.2. Kinetics of chemotherapy drug
The systemic pharmacokinetic and pharmacodynamic properties of TMZ
has been studied in detail in several studies [53, 59]. Baker et al. [59] described
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the concentrations of TMZ, MTIC and AIC in plasma in detail. Ostermann
et al. [53] collected data on TMZ concentration from blood and cerebrospinal
fluid (CSF) obtained via lumbar puncture in patients with malignant gliomas.
However due to the physiological separation of brain and tumour from both
blood and CSF (through blood-brain, blood-tumour, blood-CSF and CSF-tumour
barriers) the amount of drug reaching the tumour differs from the amount of
drug circulating in blood and CSF [60, 61]. Therefore instead of describing
a complicated mechanism with many unknown parameters based on data col-
lected from blood or CSF, we chose a simpler dynamics based directly on the
brain tissue data. Thus we will base our model on data from the study by
Portnow et al. [26] who examined TMZ concentration in intracerebral micro-
dialysis samples from peritumoural brain interstitium obtained from patients
with central nervous system tumours.
With regard to chemotherapy pharmacokinetics, we will assume, as usual
[34, 62], that the concentration of TMZ, C(t), measured in units of days decays
exponentially due to the drug clearance with a constant rate λ. It is consistent
with the fact that TMZ has linear pharmacokinetics [11]. Thus, we have to
complement Eqs. (1) with
dC
dt
= −λC. (1c)
TMZ reaches a maximal drug concentration in the brain about two hours after
administration [26, 40, 59], what is very short in comparison to the time scale of
tumour evolution in the model (of the order of years). Thus, we may treat the
whole time of oral drug administration, absorption and transport to the brain
as a discontinuous change in the drug concentration that occurs at given admin-
istration times. Such a formulation of the problem enables also the following
mathematical analysis and estimations.
Chemotherapy will consist of a sequence of doses d1, d2, . . . , dn given at times
t1 < t2 < . . . < tn. We assume that initially (at time t = t0, taken to be the
start of the tumour observation) the tumour has a certain mass P0 = P (t0) and
there are neither damaged cells, nor chemotherapy drugs within the tumour,
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thus D(t0) = 0, C(t0) = 0. Thus for t ∈ (0, t1) solving Eqs. (1) with initial
conditions given above leads to
P (t) =
KP0e
ρt
K − P0 (1− eρt)
, D(t) = 0, C(t) = 0. (2)
For t ∈ (tj , tj+1), j = 1, 2, 3, . . . , n with n being the total number of doses, the
values of P , D and C change according to Eqs. (1), while at t = tj subsequent
doses of the drug are administrated which we model as impulses, so that
P (tj) = P (t
−
j ), D(tj) = D(t
−
j ), C(tj) = C(t
−
j ) + Cj , (3)
where f(t−j ) = limt→t−
j
f(t) and Cj is the fraction of the dose dj which reaches
the tumour tissue, accounting for drug loss during transport to the brain.
The interval between doses (typically 1 day) will be chosen to be larger than
the time of whole dose elimination (reported to be around 7h [25]) and the
typical damage repair times (of the order of a few hours [63]), so that one dose
will not alter the effect of the next one.
The asymptotic behaviour of model (1) under the effect of a finite number
of doses is easy to obtain. When no drug is given for time t ≥ tn (with n being
the index of the last dosis), then C(t) = C(tn) exp(−λ(t− tn))→ 0 as t→ +∞.
As C → ∞ and P is bounded, then αPC → 0 for t → +∞. As a consequence
D′(t) < 0 for sufficiently large time. Then it is easily seen that D(t) → 0 and
P (t)→ K as t→ +∞. This behaviour is not surprising and can be interpreted
as patient death due to drug clearance and tumour regrowth. Patient death
usually occurs when the tumour reaches a critical size called the fatal tumour
burden considered to be in high-grade glioma models to be around 6 cm in
diameter [64, 65].
It is important to emphasise that model (1) intends to describe the effect
of first-line chemotherapy, since after the treatment resistant phenotypes arise
leading to the acquisition of drug resistance. Thus a detailed analysis of second-
line chemotherapy would require the introduction of more phenotypes in the
model and is beyond the scope of this research.
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2.3. Parameter estimation
To work with Eqs. (1) we need to provide realistic values for the model
parameters.
The saturation coefficient K for LGG growth will be set to the volume of
a sphere of diameter 10 cm reported to be the maximal mean tumour diameter
observed in LGG patients [30]. In fact, most patients die when the tumour
diameter is about 6 cm in size as discussed before [64, 65].
We can estimate the rate of drug decay λ using values of TMZ half-life
clearance time t1/2. From the definition of t1/2 and assuming exponential decay
as in Eqs.(1) we have
1
2
= e−λt1/2 .
To account also for the drug loss during transport to the brain we calculate
value Cj of the maximal dose dj reaching the tumour as
Cj = β · dj · b, (4)
where β is the fraction of TMZ getting to 1ml of brain interstitial fluid (from
a unit dose) and b is a surface of a patient body with j ∈ {1, . . . , n} and n being
the total number of doses d administered. Then Cj can be interpreted as an
effective dose per fraction.
The most typical chemotherapy schedule consists of cycles of 28 days with
five TMZ oral doses on days 1 to 5 followed by a break of 23 days. Standard
dose per day is 150 mg per m2 of patient body surface, which is usually around
1.6 m2 for women and 1.9 m2 for men [66] with an average of 1.7 m2 [67]. Then
in the case of the standard chemotherapy scheme we will fix dj = d = 150mg/m
2
and Cj = C0 = β · d · b.
The parameter β can be calculated using the value of maximal TMZ con-
centration Cmax for a dose of 150 mg/m
2 taken from the literature [26, 40].
Assuming that time to reach peak drug concentration in the brain is negligible
(equals 0.85−2h) in comparison to the time scale of the model, we set the initial
drug concentration C0 in the moment of its administration to the value Cmax.
A summary of the biological parameter values is presented in Table 1.
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Table 1: Biological parameters describing TMZ concentration in brain.
Parameter Description Value, references
t1/2 TMZ half-life clearance time ≃ 2h [40]
Cmax mean peak TMZ concentration 0.6µg/ml [26]
in brain interstitium
λ rate of decay of TMZ 0.3466/h Calculated
from [26, 40]
β fraction of TMZ getting 2.1 · 10−6/ml (m) Estimated
to brain interstitium 2.5 · 10−6/ml (w) from [26, 40]
3. Numerical results
3.1. Model fitting to patient data
To test if our simple model given by Eqs. (1) is able to reflect the dynamics
of LGG response to chemotherapy, we have used the model to describe volu-
metric longitudinal data of patients followed at the Bern University Hospital
between 1990 and 2013. In this study we selected data on 18 patients who
had been treated with TMZ out of a total number of 82 LGGs patients, see
Table 2. Radiological glioma growth was quantified by manual measurements
of tumour diameters on successive MRIs. The three largest tumour diameters
(D1, D2, D3) according to three reference orthogonal planes (axial, coronal and
sagittal planes) have been measured and tumour volumes have been estimated
using the ellipsoidal approximation: V = (D1 ·D2 ·D3)/2, following the standard
clinical practice [68, 69].
The inclusion criteria for patients for the purpose of model fitting in this
study included: (i) biopsy/surgery confirmed LGG (astrocytoma, oligoastrocy-
toma or oligodendroglioma), (ii) availability of at least 2 MRIs before the onset
of TMZ treatment, (iii) no other treatment given in the period of study and (iv)
availability of at least 4 MRIs after TMZ onset with at least one after the end of
the chemotherapy. 7 patients satisfied these criteria. All patients in this group
received more than 4 TMZ cycles and the mean duration of TMZ treatment was
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6.26 months.
Table 2: Characteristics of patients treated with TMZ
Age at diagnosis, mean (st. deviation), yr 47.19 (7.54)
Sex, M/F 14/4
Histology at diagnosis
Oligodendroglioma 7
Oligoastrocytoma 9
Astrocytoma 1
Unknown 1
Type of surgery
Biopsy 10
Resection 9
Radiotherapy 8
Chemotheraphy (CT) 18
Age at CT onset, mean (st. deviation), yr 51.8 (8.35)
Time from surgery to CT, mean (st. deviation), yr 3.7 (4)
Second-line CT 8
The rate of tumour cell proliferation ρ, the coefficient k describing the de-
lay in damaged cell death and the parameter of TMZ-cell kill strength α were
considered to be tumour-specific and fitted for each patient. Thus only three
parameters are unknown and the others are taken as in Table 1.
To estimate the parameter ρ we used patient data before the start of TMZ ad-
ministration since it is the only relevant parameter during that time, see Eq. (2).
The initial tumour volume P0in this equation was fixed to be the volume from
first MRI done after surgery. Then, having obtained the value of ρ, MRI data
after the onset of chemotherapy was used to estimate parameters α and k in
Eqs. (1). Model fitting was done using a weighted least squares method. To
simulate Eqs. (1), we have used the standard Matlab ODE solver based on the
Runge-Kutta 4th-order method.
Figs. 1, 6 show both the real tumour volume data obtained from the MRIs
12
(circles) together with the best fit obtained with Eqs. (1) (solid line). The model
dynamics fit the real volumetric tumour evolution well, showing an impressive
agreement with a minimal number of parameters for patients with delayed re-
sponse to chemotherapy. The minimal value of the fitted proliferation rate for
some patients is one order of magnitude smaller than values (1−5) ·10−3 day−1
observed in other studies [57, 70, 71] as in these studies the model for tumour
growth also considered a diffusive term. Some of the tumours were relatively
large, however no formation of neoangiogenesis or necrotic core was observed.
See also Supplementary material for all patients data and estimated parameters.
3.2. Tumours with faster response have worse prognosis
We have also studied how the tumour response depends on parameters fitted,
see Figs. 3, 4. We will denote by “time to radiological progression” (TRP) the
time when the tumour attains its minimum volume after the chemotherapy onset
and starts regrowing. We will refer to “growth delay” as the time for which the
tumour volume equals the initial one when regrowing after the therapy, see [57].
We will refer to “early response” when TRP is attained shortly after the end of
chemotherapy and “no response” when there was no decrease in tumour volume
detectable by radiologist. In case of frequent MRIs these times can be easily
obtained from model simulations and compared with the values obtained from
patient’s MRI volumetry. It can be estimated with an error being the time
between two subsequent MRIs. We have also computed the overall survival (OS)
as the time until reaching the fatal tumour burden defined in Sec.2.2. We have
considered only the cases of virtual tumours whose volumes decreased below
the volume at TMZ onset. Note that for the purpose of analysis of response
to TMZ, OS is computed for virtual tumours responding to TMZ and without
any other treatment in the following course of disease, thus in general could be
overestimated and thus should not be compared to the values of real-patients
overall survival.
After performing many simulations for different initial values and chemo-
therapy schemes, we conclude that both larger proliferation rates ρ and smaller
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Figure 1: Tumour volume evolution for three selected patients treated with TMZ. The begin-
ning and the end of TMZ treatment are marked with vertical dashed lines. There are shown the
volumes calculated from MRIs (circles) and from the fitted mathematical model (solid lines).
The number of TMZ cycles and the values of parameters were different for each patient. (top)
Patient treated with 5 TMZ cycles, α = 0.971918ml/µg/day, ρ = 0.001761/day, k = 0.555867.
(center) Patient treated with 11 TMZ cycles, α = 0.279911ml/µg/day, ρ = 0.000136/day,
k = 0.025617. (bottom) Patient treated with 4 TMZ cycles, α = 1.387798ml/µg/day,
ρ = 0.002416/day, k = 0.272291.
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Figure 2: Tumour volume evolution for different values of parameters. Virtual patients were
treated with 12 cycles of TMZ as in the standard fractionation scheme (see Sec.2.3) with
k = 0.5. (left) Parameter α was fixed to value 0.7ml/µg/day, ρ1 = 0.004/day, ρ2 = 0.002/day.
(right) Parameter ρ was fixed to value 0.0025/day, α1 = 0.4ml/µg/day, α2 = 0.8ml/µg/day.
The horizontal dotted lines correspond to tumour sizes equal to the fatal tumour burden.
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Figure 3: Characteristic times of tumour response for different proliferation rates ρ and dif-
ferent levels of TMZ cell kill strength α. We considered 12 cycles of TMZ as in the standard
fractionation scheme (see Sec. 2.3) for virtual patients with LGG of initial volume 40 cm3.
(left) Results for ρ = 0.0008/day, k = 0.3 and α ∈ [0.1, 1]ml/µg/day. (right) Results for
α = 0.8ml/µg/day, k = 0.3 and ρ ∈ [0.7, 8]× 10−3/day.
TMZ cell kill strengths α, lead to an earlier response to TMZ treatment. A more
systematic study is shown in Fig. 2 for two specific parameter sets, providing
representative examples. Virtual patients who responded earlier to TMZ (had
smaller TRP) had a faster regrowth and reached the fatal tumour burden earlier.
15
1
1
2
3
4
Ti
m
e 
(ye
ars
)
0.8
4
α
 (ml/µg/day)
3
5
ρ (1/d
ay) ×10-30.6 210.4
1
5
10
4
Ti
m
e 
(ye
ars
)
0.8
15
α
 (ml/µg/day)
3
20
×10-3
ρ (1/d
ay)0.6 210.4
Figure 4: Characteristic times of tumour response for different proliferation rates ρ and dif-
ferent levels of TMZ cell kill strength α. We considered 12 cycles of TMZ as in the standard
fractionation scheme (see Sec. 2.3) with k = 0.3. Values of time to radiological progression
(left), growth delay and overall survival (right) are shown for virtual patients with LGG of an
initial volume of 40 cm3.
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Figure 5: Time to radiological response and overall survival of LGGs patients treated with
TMZ. Patients were divided into two groups: in the first, denoted by circles, patients were
treated with TMZ for less than 10 months (average: 5.72, st. deviation: 3.8), in the sec-
ond group, denoted by triangles, patients were treated with TMZ for more than 10 months
(average: 13.65, st. deviation: 3.14).
Thus, a shorter TRP is an indicator of worse prognosis.
Are these model features also present in the patient’s data? Fig. 5 shows how
the overall survival rate correlates with the time to radiological progression. For
the purpose of this analysis we also included patients with only one MRI before
treatment with TMZ. We excluded (i) two patients in which only two MRIs were
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available after the end of chemotherapy showing no tumour regrowth and (ii)
one patient treated with TMZ for only 1.5 month showing no response. For each
patient TRP was estimated as the time to the MRI in which tumour volume
was the smallest after the onset of treatment. Due to the differing duration of
TMZ treatments we divided patients into a group receiving less than 10 TMZ
cycles and those receiving 10 or more cycles.
The Spearman rank correlation coefficient between TRP and OS equals 1 for
data of patients treated with TMZ for less than 10 months and 0.9047619 for
those treated with TMZ for longer time. The exact Spearman coefficient test
significance levels equal 0.008333 and 0.002282 for right-tailed tests for group of
patients treated with less and more than 10 cycles of TMZ, respectively. This
result indicates a positive correlation between TRP and OS. The significance lev-
els were calculated using R. Data on overall survival is right-censored, however
the results suggest that the early regrowth of the tumour after chemotherapy
is related to its aggressiveness. Despite therapies used after progression, those
tumours that responded faster to TMZ treatment progressed faster, suggesting
either larger proliferation potential and/or smaller TMZ cell kill strength.
4. Results (II): Analytical estimates of tumour response
4.1. Survival fraction
Up to now our analysis has been based on numerical simulations of Eqs.
(1). We can calculate the fraction of tumour cells eliminated by a single dose
of chemotherapy, which in the context of radiotherapy is usually referred to as
survival fraction. To do so, we will assume that the time of drug absorption,
distribution and elimination from the human body is much shorter than the
doubling time of the tumour cell population, what is true for LGGs. Therefore,
focusing on short-term effects of the drug we may neglect the term describing
tumour proliferation. Consequently the size of damaged cells population remains
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zero and we consider instead the simplified model
dP
dt
= −αPC, (5a)
dC
dt
= −λC. (5b)
For time before the second drug administration t1 ≤ t < t2 we have
C(t) = C0e
−λt, (6a)
P (t) = P0 exp
(α
λ
C0
(
e−λt − 1
))
. (6b)
Then we define function Sf describing the survival fraction as follows
Sf (t) =
P (t)
P0
= exp
(α
λ
C0
(
e−λt − 1
))
exp
(
z0
µ
(
e−µs − 1
))
.
Thus for long times t≫ 1/λ we obtain the formula
Sf = exp
(
−
α
λ
C0
)
. (7)
Survival fraction depends exponentially on the TMZ cell kill strength α, the
effective dose C0 and inversely on the time of exposure to chemotherapy λ. This
formula is similar to the linear term in the linear-quadratic model describing
the effect of a single dose of radiotherapy on cells [63].
4.2. Motivation and rescaled model
In the following subsection we will compute analytical estimates for the
TRP as a function of the model parameters. We will study a broad range of
chemotherapy fractionation schemes in which the time between doses is larger
than the time of cell damage repair and drug uptake, i.e. doses are separated
by more than several hours.
Without loss of generality, we can assume that the time of the first drug
administration is t1 = 0. In agreement with clinical practise, we will assume
all drug doses to be equal. Thus dj = d for j ∈ {1, . . . , n} with n being the
total number of doses. The effective dose per fraction C0 is calculated as in
Sec. 2.3. In order to obtain analytical estimates let us introduce the following
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notation. Each chemotherapy cycle is described by three parameters: the cycle
duration T (measured in days), the number of doses per cycle p, and the interval
between doses in each cycle r (measured in days). Thus, the drug is given at
times t1 = 0, t2 = r, t3 = 2r, . . . , tp = (p − 1)r, tp+1 = T , tp+2 = T + r,
. . . , tn = n/(p − 1)T + (p − 1)r. This definition allows for the description of
many different chemotherapy schemes, including those in which administration
of drug doses in a cycle is followed by some break (as T can be greater than pr).
For instance, in the clinical trial described in [17] patients were treated with
TMZ given daily for seven weeks followed by four-week breaks. For that study
we would take T = 77, r = 1, p = 49 and the drug would be administered at
days t1 = 0, t2 = 1, t3 = 2, . . . , t49 = 48, t50 = 77, t30 = 78 etc.
The total number of TMZ cycles in a general fractionation scheme described
above equals n/p and the times of drug administration are
tj = (j − 1)r +m
(
T − pr
)
, (8)
where m =
⌊
j − 1
p
⌋
is the number of completed chemotherapy cycles before
dose tj , j ∈ {1, . . . , n}. Then m ∈ {0, n/p− 1} and
j = pm+ i, (9)
i being the index of a dose within each TMZ cycle, i ∈ {1, . . . , p}.
From the first dose of chemotherapy drug at time t1 = 0, the tumour growth
and change in drug concentration are described by Eqs. (1) with initial condi-
tions: P (0) = P0, D(0) = 0, C(0) = C0. For t ∈ [tj , tj+1) and after the end of
chemotherapy the values of P , D and C change according to Eqs. (1), while
at t = tj values of functions P, D and C are as in (3) with Cj = C0 for
j ∈ {2, . . . , n}.
Let us rescale the model variables by taking x = P/K, y = D/K, z = αC/ρ,
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s = ρt to get
dx
ds
= x (1− x− y)− xz (10a)
dy
ds
= −
1
k
y (1− x− y) + xz (10b)
dz
ds
= −µz (10c)
with initial conditions: x(0) = x0 = P0/K, y(0) = 0, z(0) = z0 = αC0/ρ, where
µ = λ/ρ. The rescaled dose z0 is imposed to be given at times s1 = 0, s2, . . . , sn.
4.3. Time of response to chemotherapy
As already mentioned, one of the main observable characteristics of the
tumour response to therapy is the time to radiological progression, i.e. the
time until the tumour starts regrowing. In our mathematical framework it
is the time tTRP at which the total tumour mass attains its minimum, i.e.
P (tTRP) + D(tTRP) = min
t≥tn
{P (t) +D(t)}. In terms of rescaled variables we
look for sTRP such that
x(sTRP) + y(sTRP) = min
s≥sn
{x(s) + y(s)} .
We will focus only on cases of tumours responding to chemotherapy with α > 0,
thus showing a radiologically visible decrease in total volume. Thus, in our ap-
proach, in which only first-line chemotherapy is described and resistant cells
do not arise, tumour progression will occur after the end of chemotherapy
(sTRP ≫ sn) provided tumour growth is slow as happens in the case of LGGs.
Thus we will try to obtain explicit formulae approximating x and y for s≫ sn.
We will consider tumours with initial sizes significantly smaller than the
carrying capacity, then the Eq. (10) takes the simpler form
dx
ds
= x− xz, (11a)
dy
ds
= −
1
k
y + xz, (11b)
dz
ds
= −µz, (11c)
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with initial conditions: x(0) = x0, y(0) = 0, z(0) = z0. Then for rescaled time
TRP we have x′(sTRP) + y
′(sTRP) = 0, therefore
x(sTRP) =
1
k
y(sTRP). (12)
Eqs. (11) are a set of ordinary differential equations with impulses, the func-
tions x and y being continuous, and z being discontinuous at times sj for
j ∈ {2, . . . , n} as
z(sj) = z(s
−
j ) + z0. (13)
Since dose clearance time is about two hours we may assume that each dose is
cleared in one day, then, in the rescaled units z((sj + ρ)
−) ≈ 0 for j ∈ {1, . . . , n}.
Therefore, we can approximate
z(s) ≈


z0e
−µ(s− sj) s ∈ (sj , sj + ρ),
0 for other s,
(14)
where j = argmax
i∈{1,...,n}
{si ≤ s} . Let us define
w(s) =
∫ s
0
z(t)dt, (15a)
w0 = w(ρ) =
∫ ρ
0
z(t)dt =
z0
µ
(
1− e−µρ
)
. (15b)
We should emphasise that for s > s2, w(s) 6= z0
(
1− e−µs
)
/µ due to the ad-
ministration of the next drug dose. Furthermore, from the definition of function
z we have
w(s) =
∫ sj
0
z(t)dt+
∫ s
sj
z(t)dt = w(sj) +
∫ s−sj
0
z(t)dt ≈ (j − 1)w0 + w(s− sj)
≈

 (j − 1)w0 +
z0
µ
(
1− e−µ(s− sj)
)
s− sj ≤ ρ,
jw0 otherwise,
(16)
where j = argmax
i∈{1,...,n}
{s ≥ si} . Hence for s > sn + ρ the formulae for rescaled
proliferating and the damaged part of tumour take the form
x(s) = x0e
s− w(s) = x0e
s− nw0 , (17a)
y(s) =
∫ s
0
e−
s−t
k x(t)z(t)dt. (17b)
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We look for sTRP which fulfils condition (12). Using Eqs. (17) we have
kek˜sTRP − nw0 =
∫ sTRP
0
ek˜t− w(t)z(t)dt, (18)
sTRP =
1
k˜
[
nw0 + ln
(
1
k
∫ sTRP
0
ek˜t− w(t)z(t)dt
)]
, (19)
where k˜ = 1 + 1/k. As a result of approximations (14) and (16) we conclude
that for s ≥ sn + ρ∫ s
0
ek˜t− w(t)z(t)dt =
n∑
j=1
z0
∫ sj+ρ
sj
ek˜t− w(t)e−µ(t− sj)dt
= z0
n∑
j=1
e−(j − 1)w0 + k˜sj
∫ sj+ρ
sj
e
(k˜ − µ)(t− sj) +
z0
µ
(
e−µ(t− sj) − 1
)
dt
= z0

 n∑
j=1
e−(j − 1)w0 + k˜sj

∫ ρ
0
e
(k˜ − µ)t+ z0µ
(
e−µt − 1
)
dt. (20)
Using Taylor expansion of an exponential function for t < 1/µ we approximate
e−µt − 1 ≈


−µt 0 ≤ t < 1/µ,
−1 t ≥ 1/µ,
and obtain
∫ ρ
0
e
(k˜ − µ)t+ z0µ
(
e−µt − 1
)
dt ≈
∫ 1
µ
0
e(k˜ − µ)t− z0tdt+
∫ ρ
1
µ
e
(k˜ − µ)t− z0µ dt
=
1
k˜ − µ− z0
(
e
k˜−µ−z0
µ − 1
)
+
1
k˜ − µ
(
e
(k˜ − µ)ρ− z0µ − e
k˜−µ−z0
µ
)
=
1(
k˜ − µ− z0
)(
k˜ − µ
)
[
z0e
k˜−µ−z0
µ − k˜ + µ+
(
k˜ − µ− z0
)
e
(
k˜ − µ
)
ρ− z0µ
]
.
(21)
To compute the sum term in Eq. (20) we need the relation between dose in-
dexes j and the times of their administration sj . Taking into consideration
assumptions from Sec. 4.1 and Eqs. (8-9) we get sj =
[
(i − 1)r +mT
]
ρ, where
m ∈ {0, n/p− 1} is the number of completed chemotherapy cycles before dose
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sj , j ∈ {1, . . . , n} and i ∈ {1, . . . , p} is an index of dose within the TMZ cycle.
As a result we obtain
n∑
j=1
exp
(
−(j − 1)w0 + k˜sj
)
=
n/p−1∑
m=0
p∑
i=1
exp
(
m
(
−pw0 + k˜ρT
)
+ (i− 1)(−w0 + k˜ρr)
)
=
1− e
(
−pw0 + k˜ρT
)
n
p
1− e−pw0 + k˜ρT
·
1− e
(
−w0 + k˜ρr
)
p
1− e−w0 + k˜ρr
, (22)
where n is the total number of doses and n/p is the total number of chemo-
therapy cycles as previously stated. Then using Eqs. (19), (20) and (21) we
get
sTRP =
nw0
k˜
+
1
k˜
ln
{
z0e
k˜−µ−z0
µ − k˜ + µ+
(
k˜ − µ− z0
)
e
(
k˜ − µ
)
ρ− z0µ
}
+
1
k˜
ln


z0
(
1− e
(
−pw0 + k˜ρT
)
n
p
)(
1− e
(
−w0 + k˜ρr
)
p
)
k
(
1− e−pw0 + k˜ρT
)(
1− e−w0 + k˜ρr
)(
k˜ − µ− z0
)(
k˜ − µ
)


.
(23)
In terms of the initial time scale, the time to tumour progression can be esti-
mated as tTRP = sTRP/ρ, giving the final result
tTRP =
nw0
k˜ρ
+
1
k˜ρ
ln
{
z0e
k˜−µ−z0
µ − k˜ + µ+
(
k˜ − µ− z0
)
e
(
k˜ − µ
)
ρ− z0µ
}
+
1
k˜ρ
ln


z0
(
1− e
(
−pw0 + k˜ρT
)
n
p
)(
1− e
(
−w0 + k˜ρr
)
p
)
k
(
1− e−pw0 + k˜ρT
)(
1− e−w0 + k˜ρr
)(
k˜ − µ− z0
)(
k˜ − µ
)


.
(24)
Eq. (24) gives the time to radiological progression as a function of parameters
with relevant biological and/or therapeutical meaning. Since TRP is a metric of
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practical relevance, it is very interesting that it is possible to estimate its value
analytically.
4.4. Validation
Eq. (24) has been obtained via a number of approximations and thus it is
relevant to compare its predictions with the results of the original equation (1)
and real patient data.
To do the latter we first fix the treatment parameters to match those rou-
tinely used for TMZ therapeutic schedules. Since TMZ is given on 5 consecutive
days in cycles consisting of 28 days, we get p = 5, T = 28, r = 1. Taking dose per
fraction to be 150 mg/m2 and the other parameters as in Sec. 4.1 we can then
estimate the time of progression for the individual patients studied previously
(accounting for the number of cycles received by each patient).
Fig. 6 shows how well formula (24) estimates the response to chemotherapy
for three patients chosen from our database. The task of comparing simulation
results with real patients MRI data requires a lot of caution. In particular, we
need to take into account the limitations of calculations of tumour volume using
the method of three largest diameters. The method is only an approximation
of real tumour volume and its accuracy is limited by slice thickness, changes
in head position [72] or even by perception of medical doctor who calculate
these diameters. However in this case one can conclude that we have obtained a
satisfactory result in fit. In the future we hope that MRI data will be analysed
through automatic segmentation, e.g. with algorithm suggested by Porz et al.
[73] and the real tumour volume will be calculated more accurately.
Fig. 7 presents relative differences between TRP from the estimated for-
mula and simulations for different sets of parameters, suggesting a very good
approximation.
4.5. The study of tumour response for other chemotherapy protocols
We have also verified that Eq. (24) provides a good approximation of TRP
for model (1) for other fractionation schemes. Fig. 8 shows some examples.
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Figure 6: Tumour volume evolution for three patients treated with TMZ. Vertical dashed
lines mark the start and the end of TMZ treatment. Circles denote the volumes obtained
from MRIs and solid lines the results of the best fit using Eqs. (1). (top) Woman treated with
6 TMZ cycles, α = 0.199094ml/µg/day, ρ = 0.00022/day, k = 0.075644. (center) Man treated
with 11 TMZ cycles, α = 0.17367ml/µg/day, ρ = 0.000338/day, k = 0.019279. (bottom) Man
treated with 4 TMZ cycles, α = 0.236439ml/µg/day, ρ = 0.000701/day, k = 0.257806. The
times to radiological progression computed using Eq. (24) are marked with vertical dashed-
dotted lines, showing a very good agreement with the data and the simulations of Eqs. (1). The
relative differences between tTRP calculated from Eq. (24) and from Eqs. (1) were respectively
0.042043, 0.041671 and 0.037481 years, for the selected patients.
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Figure 7: Relative percentage difference between time to radiological progression estimated
from simulations of model (1) and formula (24). We considered 12 cycles of TMZ as in the
standard fractionation scheme (see Sec. 2.3) for virtual patients with LGG having an initial
volume of 40 cm3. Results for ρ = 0.0004/day, α = 0.4ml/µg/day, k ∈ [0.02, 1] (left) and
ρ = 0.0008/day, α = 0.8ml/µg/day, k ∈ [0.02, 1]. (center) Results for α = 0.8ml/µg/day,
k = 0.3 for ρ ∈ [0.2, 8] × 10−3/day (left) and α = 0.8ml/µg/day, k = 0.3 for ρ ∈ [0.2, 3] ×
10−3/day. (bottom) Results for ρ = 0.0008/day, k = 0.6 and α ∈ [0.3, 1.5]ml/µg/day (left)
and ρ = 0.0004/day, k = 0.3 and α ∈ [0.15, 1.5]ml/µg/day (right).
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Figure 8: Tumour volume evolution for virtual patients simulated from Eqs. (1). Times to
radiological progression estimated from Eq. (24) are marked with vertical dashed-dotted lines.
Values of parameters were k = 0.5, α = 0.4ml/µg/day and ρ = 0.005/day. The start and the
end of TMZ treatment are marked with vertical dashed lines. (left) 9 TMZ cycles of 34 days
with doses given every 2 days for a total of 10 doses per cycle. The dose per fraction was
d=100 mg/m2. (right) 18 TMZ cycles of 77 days with doses given every 7 days for a total of 10
doses per cycle. The dose per fraction was d=50 mg/m2. Relative differences between times
free of progression calculated from Eq. (24) and estimated from simulations were 0.026756
and 0.025303 years, respectively.
5. Discussion and therapeutic implications
Due to the observed clinical significance of TMZ there is an increasing in-
terest in studying its characteristics. Up to now there have been a great deal
of relevant research into the pharmacokinetic/pharmacodynamic properties of
TMZ [26, 40, 53, 59], its specific mechanism of action [12, 14, 25, 56] and mod-
elling its concentration dynamics in vitro and in vivo [74–76]. However there
are fewer mathematical studies of patient response to TMZ in LGGs. Here we
intended to construct a mathematical model which would enable understanding
of delayed response to chemotherapy observed in LGGs without using an exces-
sive number of unknown parameters. Cells were assumed to grow logistically,
chemotherapy drug kinetics and its effect on glioma cells was based on TMZ
concentration in brain tissue [26] and clinical observations [30, 31, 55]. Note
that even the authors of the very complicated model [76], constructed for the
purpose of describing pharmacokinetics and pharmacodynamis of TMZ, vali-
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dated their model for human cerebral tumours on the basis of data of Portnow
et al. [26]. It is remarkable that a simple model such as the one presented here
with essentially only three unknown parameters (α, ρ, k) is able to describe the
response of real patients to a variable number of cycles of TMZ.
The model also shows a correlation between a short time to radiological
progression and a poor virtual patient outcome. We may conclude that time
to radiological progression can be useful as a measure of tumour aggressiveness
due to its dependence on tumour-specific parameters: proliferation rate ρ and
TMZ cell kill strength α (see Figs. 3,4). Our data on patients treated with first-
line TMZ suggests likewise that despite other therapies used in the follow-up,
patients who had shorter estimated TRP had worse prognosis. Such observation
has been made for radiotherapy [77, 78], but so far no similar analysis of response
to TMZ has been done. The velocity of tumour decrease after radiotherapy (or
equivalently time of progression-free survival) is strongly associated with the
risk of rapid progression and poor overall survival. Here we suggest a similar
result for the response to chemotherapy, namely that short time to radiological
progression results in shorter overall survival.
This outcome makes us think of the possibility of using chemotherapy to
probe tumours, hence providing estimates of tumour-specific parameters ρ and
α. We could apply a small number of cycles of TMZ causing minimal toxicity
and monitor with MRI the tumour response to chemotherapy. In order to assure
the reasonable measurement error, we would need at least two measurements
before and three after TMZ onset. We predict that the time horizon would be
of around 2 years from the time of the first MRI. We believe it could be feasible
as even up to now there were cases when MRI was performed three times a year.
Based on our database there will be no progression at this time horizon. Such
a procedure can be used as a novel way to assess tumour aggressiveness. Our
mathematical model suggests that tumour which attains its minimal volume
early after a short course of TMZ treatment (has shorter TRP) may be more
aggressive, therefore in such a case the remaining TMZ dose has to be finished
as soon as possible and other therapeutic options (further surgery if feasible or
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radiotherapy) should be considered. Such a concept can be supported also by
thein vitro results of Roos et al. [56], who shown that higher proliferation rates
accelerate apoptosis after TMZ treatment, thus in terms of our idea, shorter
TRP.
This idea resembles that described in [57], but with chemotherapy instead
of radiotherapy. Although the modelling principles are similar, from the clinical
point of view the use of TMZ is a much more interesting as a way to probe
a tumour than the use of radiotherapy as its side-effects are long-term and
non-reversible. On the other hand, TMZ has significantly lower and largely
reversible side-effects. Moreover, radiotherapy is well known to induce changes
in the MRI images due to inflammation which may distort the analysis of the
tumour response. Finally, TMZ is easily managed because it is administered
orally.
6. Conclusions
We have build a model which is simple from the mathematical point of
view, but which incorporates the basic biological features of LGG growth and
the response to chemotherapy.
The model is able to describe response to TMZ with a minimal number of
parameters and suggests that tumours having a shorter time to radiological re-
sponse after TMZ treatment may be more aggressive in terms of proliferation
potential. We plan to reassess this observation using a larger data set, if possi-
ble. In this case we would like also to verify whether the survival curves obtained
can be fitted for a cohort of virtual patients, as done by Kirkby et al. [79].
Moreover, we propose a paradigm for probing tumour with TMZ which could
be used in clinical practice. We have also found an equation giving the time free
of progression as a function of the relevant biological and therapeutic parame-
ters. In future studies it may be helpful in designing treatment schedules giving
the longest TRP possible with the additional condition for the toxicity level.
In order to address other clinically relevant issues and the biological per-
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spective several improvements to the present model will be implemented in the
near future. First it may be appropriate to include more biological details such
as the potential existence of the so-called cancer initiating cells or cancer stem
cells. Also incorporating different phenotypes may be relevant to describe the
process of acquiring resistances to TMZ.
It would also be interesting to find the minimal doses and minimal fre-
quency of therapy such that the solution (namely tumour mass) stays below
a given threshold. In principle, survival could be improved and chemoresistance
deferred using metronomic fractionations, i.e. schedules consisting of many,
equally spaced and generally low doses of chemotherapeutic drugs without ex-
tended rest periods (see e.g. [80, 81]).
We hope that optimized cancer treatment protocols on the basis of models
such as the one presented in this paper may become in the future a standard
element of personalised medicine.
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